BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Topotecan: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sichuan Baili Pharmaceutical Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Hansoh BioMedical R&D Company, Genmab, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair, Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06500026 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | Small Cell Lung Cancer | active not recruiting | 722 |
| 2026-12-30 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers | not yet recruiting | 430 |
| 2026-12-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT07145333 Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms | SCLC | active not recruiting | 600 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08-20 | P3 | Hansoh BioMedical R&D Company | NCT06498479 ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | Small Cell Lung Cancer | completed | 461 |
| 2026-08-18 | P3 | Genmab GMAB | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Platinum-resistant Ovarian Cancer | active not recruiting | 584 |
| 2026-05-31 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Ovarian Cancer | recruiting | 440 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.